A recombinant porcine acute diarrhea syndrome coronavirus, use and vaccine

The construction of recombinant pig acute diarrhea syndrome coronavirus targeting peptide tandem through DNA homologous recombination engineering and Gibson assembly technology has solved the problem that existing vaccines cannot effectively induce mucosal immunity, and achieved a comprehensive combination of epidemic diarrhea in pigs and acute diarrhea in pigs Effective prevention and control of coronaviruses has provided safe and efficient vaccine solutions.

CN118360258BActive Publication Date: 2024-12-06GUANGZHOU ANHE ANIMAL HEALTH BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410461333.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-17
Publication Date
2024-12-06
Estimated Expiration
2044-04-17

AI Technical Summary

Technical Problem

The existing coronavirus vaccines for epidemic diarrhea in swine and acute diarrhea syndrome in swine cannot effectively induce mucosal immune response, and the lack of effective vaccines for the new coronavirus has led to serious economic losses and disease control problems in the pig industry.

Method used

Using DNA homologous recombination engineering, Gibson assembly technology and reverse screening operating system, a recombinant pig acute diarrhea syndrome coronavirus targeting peptide tandem swine epidemic diarrhea virus gene was constructed. As a candidate vaccine strain for the 2-link vaccine, it replaced ORF3a Gene insertion of targeted peptides Co1, DCpep or Co1+DCpep to improve the immune effect of the vaccine.

Benefits of technology

It has achieved good genetic stability and in vitro replication ability, has good safety and mucosal immune stimulation effect, and provides an effective candidate vaccine against co-infection of SADS-CoV and PEDV, which significantly improves the epidemic diarrhea virus and pigs. Clinical protection effect of acute diarrhea syndrome coronavirus.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118360258B_ABST
    Figure CN118360258B_ABST
Patent Text Reader

Abstract

The present invention belongs to the biological field, and discloses a recombinant porcine acute diarrhea syndrome coronavirus, which is obtained by replacing the ORF3a gene of SADS-CoV with a COE+S1D fragment of the porcine epidemic diarrhea virus S gene connected with a targeting peptide gene; the COE+S1D fragment refers to a tandem epitope formed by tandem connection of the COE antigenic epitope and the S1D antigenic epitope of the porcine epidemic diarrhea virus S gene. The present invention combines DNA homologous recombination engineering technology, Gibson assembly technology and reverse screening operating system to finally obtain a recombinant porcine acute diarrhea syndrome coronavirus with a targeting peptide tandem porcine epidemic diarrhea virus gene, which has good safety and mucosal immune stimulation effects, and can be used as a candidate vaccine strain for a bivalent vaccine of porcine epidemic diarrhea virus and porcine acute diarrhea syndrome coronavirus. At the same time, the present invention also discloses the use of the recombinant porcine acute diarrhea syndrome coronavirus and a vaccine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the biological field, and specifically relates to a recombinant porcine acute diarrhea syndrome coronavirus, its use and a vaccine. Background Art

[0002] Swine Acute Diarrhea Syndrome Coronavirus (SADS-CoV) is an enveloped single-stranded positive-strand RNA virus. It belongs to the genus Coronavirus of the family Coronaviridae in systematic classification and can cause severe diarrhea in piglets within 5 days of age. The SADS-CoV genome size is about 27kb, including 5'-UTR, 3'-UTR and 9 coding frames. Among them, the auxiliary protein gene of SADS-CoV is a non-essential gene for viral proliferation and assembly, which can be inserted into foreign genes and used as a live virus vector. At the same time, the pathogenicity of SADS-CoV is relatively weak, and it only causes disease in piglets within 5 days of age. The lack of its auxiliary protein also has the effect of further weakening the virulence of the virus, so it is safe as a vaccine vector.

[0003] Porcine epidemic diarrhea (PED) is caused by porcine epidemic diarrhea virus (PEDV), and its symptoms include diarrhea, vomiting, anorexia, dehydration and weight loss in piglets. Pigs of all ages can be infected and show varying degrees of symptoms, but piglets are the most severely affected, with a mortality rate of up to 100%. The disease is currently wreaking havoc on the pig industry.

[0004] PEDV and SADS-CoV, as clinically very important pathogens that cause diarrhea in piglets, seriously restrict the global pig farming industry and cause huge economic losses to the pig farming industry. Therefore, it is urgent to develop and utilize recombinant live vector vaccines to better defend against diseases caused by PEDV and SADS-CoV. Studies have shown that the S gene of coronavirus is associated with its protective immunity. The above two coronaviruses mainly infect pigs through the intestinal mucosal surface. Therefore, the induction of mucosal immunity and systemic immunity is the key to protecting animals from diarrhea-related coronaviruses. At present, commercial PEDV vaccines include inactivated vaccines and modified live vaccines. The strains are updated slowly and are mainly administered through intramuscular immunization, which cannot induce effective mucosal immune responses to prevent infection with the current PEDV epidemic strains. SADS-CoV is a new coronavirus, and there is currently no effective vaccine application. Therefore, the development of safe and effective vaccines is of great significance for the prevention and control of the above two viruses.

[0005] The applicant has previously applied for an invention patent CN114657213B, which discloses a porcine acute diarrhea syndrome coronavirus artificial chromosome recombinant vector and its construction method and application. The applicant has successfully constructed an infectious clone of the virus strain SADS-CoV-WT and established a method for knocking out or inserting exogenous genes at the auxiliary protein gene ORF3a and ORF7a / b based on DNA homologous recombination engineering and ccdB reverse screening system.

[0006] The present invention is further developed based on the above research to improve the immune effect of the vaccine. Summary of the invention

[0007] In view of the shortcomings of the prior art, the object of the present invention is to provide a recombinant porcine acute diarrhea syndrome coronavirus. The present invention combines DNA homologous recombination engineering technology, Gibson assembly technology and reverse screening operating system to finally obtain a recombinant porcine acute diarrhea syndrome coronavirus with a targeting peptide tandem with the porcine epidemic diarrhea virus gene. The recombinant porcine acute diarrhea syndrome coronavirus has good safety and mucosal immune stimulation effects, and can be used as a candidate vaccine strain for the porcine epidemic diarrhea virus and porcine acute diarrhea syndrome coronavirus bivalent vaccine.

[0008] At the same time, the invention also discloses the use and vaccine of the recombinant porcine acute diarrhea syndrome coronavirus.

[0009] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0010] A recombinant porcine acute diarrhea syndrome coronavirus, obtained by replacing the ORF3a gene of SADS-CoV with the COE+S1D fragment of the S gene of porcine epidemic diarrhea virus connected with a targeting peptide gene;

[0011] The COE+S1D fragment refers to a tandem epitope formed by the tandem connection of the COE antigenic epitope and the S1D antigenic epitope of the S gene of porcine epidemic diarrhea virus.

[0012] In the above-mentioned recombinant porcine acute diarrhea syndrome coronavirus, the porcine epidemic diarrhea virus S gene connected with the targeting peptide gene is any one of the following three genes:

[0013] The COE+S1D fragment of the porcine epidemic diarrhea virus S gene with the M cell targeting peptide Co1 concatenated;

[0014] The porcine epidemic diarrhea virus S gene COE+S1D fragment connected in series with the DC cell targeting peptide DCpep;

[0015] The COE+S1D fragment of the S gene of porcine epidemic diarrhea virus was concatenated with the M cell targeting peptide Co1 and the DC cell targeting peptide DCpep.

[0016] More specifically, SADS-CoV is the recombinant porcine acute diarrhea syndrome coronavirus described in CN114657213B.

[0017] The preparation method of the recombinant porcine acute diarrhea syndrome coronavirus of the porcine epidemic diarrhea virus S gene COE+S1D fragment connected in series with the M cell targeting peptide Co1 is as follows:

[0018] (1) Loading homology arms to both ends of amp-ccdB by PCR to obtain a screening marker fragment with ORF3a homology arms at both ends;

[0019] (2) The M cell targeting peptide Co1 and homology arms were loaded into the right side and both ends of the COE+S1D region of the PEDV S gene by PCR to obtain the PEDV S gene COE+S1D fragment with the targeting peptide Co1 and the ORF3a homology arms;

[0020] (3) The linear fragment of step (1) was recombined with the pBeloBAC11-cm-CI-SADS-CoV-WT-HDVrz-SV40polyA infectious clone (CN114657213B, described in S10) by DNA homologous recombination engineering;

[0021] (4) using the preset restriction site to cut off the amp-ccdB screening marker fragment, and assembling it with the PEDV S gene COE+S1D fragment obtained in step (2) through Gibson assembly to obtain the targeting peptide Co1 that replaces the ORF3a gene, the PEDV S gene COE+S1D recombinant plasmid and the recombinant porcine acute diarrhea syndrome coronavirus.

[0022] The preparation method of the recombinant porcine acute diarrhea syndrome coronavirus of the porcine epidemic diarrhea virus S gene COE+S1D fragment connected in series with the DC cell targeting peptide DCpep is as follows:

[0023] (1) Loading homology arms to both ends of amp-ccdB by PCR to obtain a screening marker fragment with ORF3a homology arms at both ends;

[0024] (2) The DC cell targeting peptide DCpep and homology arms were loaded into the right side and both ends of the COE+S1D region of the PEDV S gene by PCR to obtain the PEDV S gene COE+S1D fragment with the targeting peptide DCpep and the ORF3a homology arms;

[0025] (3) The linear fragment of step (1) was recombined with the pBeloBAC11-cm-CI-SADS-CoV-WT-HDVrz-SV40polyA infectious clone by DNA homologous recombination engineering;

[0026] (4) using the preset restriction site to cut off the amp-ccdB screening marker fragment, and assembling it with the PEDV S gene COE+S1D fragment obtained in step (2) through Gibson assembly to obtain the targeting peptide DCpep that replaces the ORF3a gene, the PEDV S gene COE+S1D recombinant plasmid and the recombinant porcine acute diarrhea syndrome coronavirus in series.

[0027] The preparation method of the recombinant porcine acute diarrhea syndrome coronavirus of the porcine epidemic diarrhea virus S gene COE+S1D fragment connected in series with the M cell targeting peptide Co1 and the DC cell targeting peptide DCpep is as follows:

[0028] (1) Loading homology arms to both ends of amp-ccdB by PCR to obtain a screening marker fragment with ORF3a homology arms at both ends;

[0029] (2) The M cell targeting peptide Co1, DC cell targeting peptide DCpep and homology arms were loaded into the right side and both ends of the COE+S1D region of the PEDVS gene by PCR to obtain the PEDV S gene COE+S1D fragment with the targeting peptide Co1+DCpep and ORF3a homology arms;

[0030] (3) The linear fragment of step (1) was recombined with the pBeloBAC11-cm-CI-SADS-CoV-WT-HDVrz-SV40polyA infectious clone by DNA homologous recombination engineering;

[0031] (4) Using the preset restriction site to cut off the amp-ccdB screening marker fragment, and assembling it with the PEDV S gene COE+S1D fragment obtained in step (2) through Gibson assembly to obtain the targeting peptide Co1+DCpep that replaces the ORF3a gene, the PEDV S gene COE+S1D recombinant plasmid and the recombinant porcine acute diarrhea syndrome coronavirus in series.

[0032] At the same time, the present invention also discloses the use of the recombinant porcine acute diarrhea syndrome coronavirus as described above in the preparation of vaccines.

[0033] The recombinant virus infectious clone prepared as above can be used as a genetic engineering vaccine or as an immunogen for preparing specific antibodies through virus rescue. The specific antibodies can be used to treat porcine epidemic diarrhea virus and porcine acute diarrhea syndrome coronavirus infection; they can also prevent porcine epidemic diarrhea virus and porcine acute diarrhea syndrome coronavirus infection; they can also prevent or treat other diseases directly caused by porcine epidemic diarrhea virus and porcine acute diarrhea syndrome coronavirus infection.

[0034] Therefore, the present invention also provides a recombinant porcine acute diarrhea syndrome coronavirus vaccine (generally a live viral vector vaccine) comprising a DCpep targeting peptide that replaces the ORF3a gene and a porcine epidemic diarrhea virus gene in series.

[0035] The present invention also provides a specific antibody prepared by using a recombinant porcine acute diarrhea syndrome coronavirus in which a DCpep targeting peptide replacing an ORF3a gene and a porcine epidemic diarrhea virus gene are connected in series as an immunogen.

[0036] The present invention also provides a drug for specific antibodies prepared by using a recombinant porcine acute diarrhea syndrome coronavirus as an immunogen, comprising a DCpep targeting peptide replacing the ORF3a gene and a porcine epidemic diarrhea virus gene in series.

[0037] Since there are multiple regions on SADS-CoV for inserting foreign genes, the present invention also provides the use of a recombinant porcine acute diarrhea syndrome coronavirus containing a DCpep targeting peptide that replaces the ORF3a gene and a porcine epidemic diarrhea virus gene in series as a vaccine vector.

[0038] Finally, the present invention also discloses a vaccine containing the recombinant porcine acute diarrhea syndrome coronavirus as described above.

[0039] The present invention selects to use SADS-CoV virus BAC as a vector for inserting foreign genes because the pathogenicity of SADS-CoV virus itself is relatively weak, and good safety can be guaranteed after attenuation. Secondly, the ORF3a position of the SADS-CoV vector can successfully insert and express foreign genes with a size of 1-2 kb, and theoretically allows the insertion of the S gene antigen epitope and targeting peptide fragment of PEDV. However, in order to ensure that all foreign genes related to the present invention can be successfully inserted into the SADS-CoV virus vector and the foreign genes can be successfully expressed, at least the following difficulties need to be overcome:

[0040] (1) Selection of exogenous gene insertion site: Previous studies have found that the insertion site of the exogenous gene significantly affects the expression efficiency of the exogenous gene. The present invention has designed multiple experiments and found that the exogenous gene can be effectively expressed by selecting the insertion site. This has been verified by fluorescent reporter genes.

[0041] (2) Since the ORF3a of SADS-CoV is located in the middle part of the viral genome and has some sequence overlap with the viral structural gene in the front and back, we chose to replace as much of the original ORF3a gene as possible without affecting the adjacent gene expression frame and its transcriptional regulatory sequence and express the exogenous gene with the help of its original expression pattern. This can ensure the stability of the exogenous gene to the greatest extent and also weaken the virulence of the virus.

[0042] Compared with the prior art, the present invention has the following beneficial effects:

[0043] 1. The replacement of exogenous genes of conventional recombinant viruses mostly requires the use of enzyme cutting sites and restriction endonucleases, but because the genome of coronavirus is large and sequencing is cumbersome, the conventional exogenous gene replacement method is more limited. The present invention takes into account the characteristics of the SADS-CoV genome and adopts a method combining DNA homologous recombination engineering and reverse screening operating system to replace exogenous genes. This method can quickly complete the traceless operation of viral genes and the insertion of exogenous genes.

[0044] 2. The present invention successfully constructed three recombinant porcine acute diarrhea syndrome coronavirus infectious clones expressing targeting peptides and PEDV S gene COE+S1D in series, and the rescued recombinant porcine acute diarrhea syndrome coronavirus can be continuously propagated on Vero cells for at least 15 generations and can show stable lesions, and successfully express foreign genes, indicating that the three recombinant viruses have good genetic stability and in vitro replication ability, and the three recombinant viruses have good safety and mucosal immune stimulation effects after immunizing sows, and can provide good clinical protection for their suckling piglets. The invention provides a method for constructing a two-in-one candidate vaccine that enhances the immune effect against SADS-CoV and PEDV co-infection by targeting M cells and DC cells, and provides a candidate vaccine strain for the treatment and prevention of porcine acute diarrhea syndrome coronavirus and porcine epidemic diarrhea virus disease infection. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] Figure 1 Schematic diagram of the structures of three recombinant SADS-CoV infectious clones implemented in the present invention;

[0046] Figure 2 The PCR amplification diagram of the linear fragments required for constructing three recombinant SADS-CoV infectious clones for the present invention; wherein, M is Takara DL5,000 Marker, lane 1 represents the amp-ccdB fragment with ORF3a homology arm, lane 2 represents the Co1 targeting peptide with ORF3a homology arm connected in series with the PEDV S gene COE+S1D fragment; lane 3 represents the DCpep targeting peptide with ORF3a homology arm connected in series with the PEDV S gene COE+S1D fragment; lane 4 represents the Co1+DCpep targeting peptide with ORF3a homology arm connected in series with the PEDV S gene COE+S1D fragment;

[0047] Figure 3PstI restriction enzyme digestion map of the recombinant plasmid with ORF3a replaced; M is NEB 1kb Ladder, and lanes 1 to 3 represent plasmids pBeloBAC11-cm-CI-SADS-CoV-WT-HDVrz-SV40polyA-△ORF3a-PEDV S(COE+S1D)-Co1, pBeloBAC11-cm-CI-SADS-CoV-WT-HDVrz-SV40polyA-△ORF3a-PEDV S(COE+S1D)-DCpep, and pBeloBAC11-cm-CI-SADS-CoV-WT-HDVrz-SV40polyA-△ORF3a-PEDV S(COE+S1D)-Co1-DCpep, respectively;

[0048] Figure 4 PCR identification diagram of the recombinant plasmid replacing the ORF3a position; M is Takara DL5000 Marker, and lanes 1 to 3 represent plasmids pBeloBAC11-cm-CI-SADS-CoV-WT-HDVrz-SV40polyA-△ORF3a-PEDV S(COE+S1D)-Co1, pBeloBAC11-cm-CI-SADS-CoV-WT-HDVrz-SV40polyA-△ORF3a-PEDV S(COE+S1D)-DCpep, and pBeloBAC11-cm-CI-SADS-CoV-WT-HDVrz-SV40polyA-△ORF3a-PEDV S(COE+S1D)-Co1-DCpep, respectively;

[0049] Figure 5 Vero cells were inoculated with the rescued virus for 24 hours. Figures A to C represent the cytopathic effects of the viruses rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1, rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-DCpep, and rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1-DCpep, respectively. Figure D represents Mock: blank Vero cells.

[0050] Figure 6This is a PCR detection diagram of the ORF3a position of the rescued virus F2 generation; M is Takara DL5000 Marker, and lanes 1 to 3 correspond to the viruses rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1, rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-DCpep, and rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1-DCpep, respectively;

[0051] Figure 7 PCR amplification of the target gene at the ORF3a position after 20 consecutive passages in Vero cells to rescue the virus; M is Takara DL5000 Marker, lanes 1 to 7 correspond to F2, F5, F8, F11, F14, F17, and F20 of the detection virus rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1, lanes 9 to 15 correspond to F2, F5, F8, F11, F14, F17, and F20 of the detection virus rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-DCpep, lanes 17 to 23 correspond to F2, F5, F8, F11, F14, F17, and F20 of the detection virus rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1-DCpep, lanes 8, 16, and 24 correspond to the detection virus rSADS-CoV-WT as a control;

[0052] Figure 8 To rescue the proliferation curve of the virus in Vero cells;

[0053] Fig. 9 It is a Western blot detection diagram of the expression of recombinant virus exogenous genes; Lanes 1 to 3 correspond to the PEDV exogenous gene expression identification results of the viruses rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1, rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-DCpep, and rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1-DCpep, respectively, and Lane 4 is a blank control Mock;

[0054] Fig.10It is an IFA detection diagram of the expression of recombinant virus exogenous genes; Figures A to C are the IFA detection of the expression of rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1, rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-DCpep, and rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1-DCpep exogenous genes, respectively. Figure D represents Mock: blank Vero cells;

[0055] Fig.11 Figures 1 and 2 are the results of the detection of dendritic cell subsets and T lymphocyte subsets in pregnant sows after immunization with the recombinant virus; Figures A to F are the flow cytometry detection results of dendritic cell subsets CD11c in the peripheral blood of sows in the rSADS-CoV-WT-△NS3a-PEDV(COE+S1D), rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1, rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-DCpep, rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1-DCpep immunization groups, commercial inactivated vaccine immunization groups and blank control groups; Figures G to L are the results of the flow cytometry detection of dendritic cell subsets CD11c in the peripheral blood of sows in the rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1, rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-DCpep immunization groups, commercial inactivated vaccine immunization groups and blank control groups, respectively. Flow cytometry results of dendritic cell subset CD80 in peripheral blood of sows in rSADS-CoV-WT-△NS3a-PEDV(COE+S1D), rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1, rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-DCpep, rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1-DCpep immunization groups, commercial inactivated vaccine immunization groups and blank control groups; M~P are statistical graphs of percentages of dendritic cell subsets CD11c, CD80, T cell subsets CD3+4+, CD3+8+, respectively;

[0056] Fig.12 This is the ELISA test chart of the serum PEDV IgG level of piglets born from sows immunized with the recombinant virus at 5 days old;

[0057] Fig.13 This is a statistical chart of the cumulative clinical diarrhea scores of piglets after PEDV challenge;

[0058] Fig.14 This is the survival curve of piglets after PEDV challenge;

[0059] Fig.15 This is a statistical chart of the cumulative daily weight gain of piglets after PEDV challenge;

[0060] Fig.16This is a statistical chart of daily virus excretion in piglets after PEDV challenge;

[0061] Fig.17 Figure 2 shows the lesions of piglets after autopsy after PEDV challenge; Figures A to G are rSADS-CoV-WT-△NS3a-PEDV (COE+S1D) immunized group, rSADS-CoV-WT-△NS3a-PEDV (COE+S1D)-Co1 immunized group, rSADS-CoV-WT-△NS3a-PEDV (COE+S1D)-DCpep immunized group, rSADS-CoV-WT-△NS3a-PEDV (COE+S1D)-Co1-DCpep immunized group, PEDV commercial inactivated vaccine immunized group, positive control group, and negative control group, respectively;

[0062] Fig.18 This is the result of quantitative detection of pathogens in the duodenum, jejunum and ileum tissues of piglets after PEDV challenge;

[0063] Fig.19 These are H&E staining images of pathological sections of the duodenum, jejunum, and ileum after challenge with PEDV; Figures A to G are rSADS-CoV-WT-△NS3a-PEDV (COE+S1D) immunized group, rSADS-CoV-WT-△NS3a-PEDV (COE+S1D)-Co1 immunized group, rSADS-CoV-WT-△NS3a-PEDV (COE+S1D)-DCpep immunized group, rSADS-CoV-WT-△NS3a-PEDV (COE+S1D)-Co1-DCpep immunized group, PEDV commercial inactivated vaccine immunized group, positive control group, and negative control group, respectively;

[0064] Fig. 20 These are immunohistochemical images of pathological sections of the duodenum, jejunum, and ileum after challenge with PEDV; Figures A to G are rSADS-CoV-WT-△NS3a-PEDV (COE+S1D) immunized group, rSADS-CoV-WT-△NS3a-PEDV (COE+S1D)-Co1 immunized group, rSADS-CoV-WT-△NS3a-PEDV (COE+S1D)-DCpep immunized group, rSADS-CoV-WT-△NS3a-PEDV (COE+S1D)-Co1-DCpep immunized group, PEDV commercial inactivated vaccine immunized group, positive control group, and negative control group, respectively; DETAILED DESCRIPTION

[0065] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0066] Example 1 Construction of a recombinant plasmid replacing the ORF3a position

[0067] Primer design principles: When designing primers, preset AscI restriction sites at both ends of amp-ccdB. Design homology arms between each amplification primer sequence, with 30-60 bp overlap between primers. The primers are shown in SEQ ID NO. 1-9 and were synthesized by Sangon Biotech (Shanghai) Co., Ltd.

[0068] For information on primers, refer to Table 1 below;

[0069] Table 1 Primer sequence list

[0070]

[0071]

[0072]

[0073]

[0074]

[0075] PCR amplification program: 94°C for 4 min; 98°C for 15 s, 55°C for 5 s, 72°C for 1 min, set to 32 cycles; extend at 72°C for 10 min, and store at 4°C.

[0076] The PCR amplification reaction system was: PrimeSTAR Max DNA Polymearse 25 μL, upstream and downstream primers (10 pmol / μL) 0.5 μL each, template 0.5 μL, and ddH2O was added to make up to 50 μL.

[0077] Gel recovery of amplified products: Each PCR product was placed on a 1% agarose gel for electrophoresis, and the voltage and time on the electrophoresis instrument were set to 125V and 30min respectively. After the electrophoresis, under the irradiation of the UV light of the gel imager, the gel at the target fragment band was carefully cut and placed in a sterilized 2mL EP tube, and the DNA fragments were recovered according to the instructions of the gel recovery kit (TIANGEN, DP214-03).

[0078] 1. Amplification of linear fragments

[0079] a. Preparation of amp-ccdB fragment

[0080] Using primers SEQ ID NO.1~2 (including primers △NS3a-ampccdB-F(WYBD) and △NS3a-ampccdB-R(WYBD) respectively), PCR amplification was performed to obtain the amp-ccdB fragment with the ORF3a homology arm (same as paragraph 132 of the CN114657213B specification). After gel electrophoresis, the linear fragment was recovered from the gel for use.

[0081] b. Preparation of exogenous gene targeting peptide Co1 / DCpep / Co1+DCpep tandem with PEDV S gene COE+S1D fragment

[0082] Using primers SEQ ID NO.3 to 9 (including primers △NS3a-PEDV-F (WYBD), PEDV-Co1-R1, PEDV-Co1-R2, PEDV-DCpep-R1, PEDV-DCpep-R2, PEDV-Co1-DCpep-R1, PEDV-Co1-DCpep-R2, respectively), the viral genome cDNA obtained by reverse transcription was used as a template to amplify the exogenous gene targeting peptide Co1 / DCpep / Co1+DCpep tandem PEDV S gene COE+S1D fragment with ORF3a homology arms. After gel electrophoresis, the linear fragment was recovered from the gel for use.

[0083] 2. Preparation of competent cells of Escherichia coli GB08-red-gyrA462

[0084] Inoculate E. coli GB08-red-gyrA462 in 1 mL of LB medium and culture overnight at 30°C and 950 rpm. The next day, transfer 70 ul to a new 1.5 mL EP tube containing 1.3 mL of LB medium and shake at 30°C and 950 rpm for 2 hours. Centrifuge at 9500 rpm for 1 min to collect the cells, add 1 mL of ddH2O, centrifuge at 9600 rpm for 1 min, and discard the supernatant; add 1 mL of ddH2O, centrifuge at 9700 rpm for 1 min, and discard the waste liquid to obtain the prepared competent state.

[0085] 3. Re-transform the pBeloBAC11-cm-CI-SADS-CoV-WT-HDVrz-SV40polyA plasmid into E.coli GB08-red-gyrA462 competent cells

[0086] See paragraph 108 of the CN114657213B specification for pBeloBAC11-cm-CI-SADS-CoV-WT-HDVrz-SV40polyA plasmid;

[0087] Add 200ng of pBeloBAC11-cm-CI-SADS-CoV-WT-HDVrz-SV40polyA plasmid to the GB08-red-gyrA462 competent cell, gently pipette and mix evenly, then transfer to an electroporation cup and electroporate at 1350V. Resuscitate at 30℃950rpm for 1h, centrifuge at 10000rpm for 1min, discard the supernatant, and resuspend the bacteria. Take 50μL of the resuspended bacterial solution, streak and spread on an LB plate containing cm resistance. Place it face up in a 30℃ incubator for 1h, then invert and culture overnight. Pick a single colony, extract the plasmid, and perform enzyme digestion verification.

[0088] 4. amp-ccdB recombination replaces ORF3a position

[0089] In the previous step of overnight culture, the correct single clone was verified by restriction digestion, and the bacteria were shaken at 30℃950rpm for 2h after transfer. After adding 35μLL-Arabinaose for induction for 40min, the bacteria were collected by centrifugation and washed. 200ng of the amp-ccdB fragment prepared in step 1 for replacing the ORF3a gene on the SADS-CoV genome was added respectively, after 1350V electrotransformation, 30℃950rpm recovery for 1h, the collected bacteria were resuspended, coated on the cm+amp resistant LB plate, and cultured at 30℃ overnight. Pick a single colony, extract the plasmid, and perform restriction digestion verification and PCR verification.

[0090] 5. Using ccdB reverse screening, the recombinant plasmids with exogenous gene targeting peptide Co1 / DCpep / Co1+DCpep tandem with PEDV S gene COE+S1D were obtained at ORF3a position.

[0091] The bacteria with the amp-ccdB plasmid obtained in step 4 were inoculated into 100 mL conical flasks containing cm+amp resistant LB culture medium and cultured overnight at 30°C and 200 rpm. The plasmid was extracted according to the instructions of the TIANGEN kit for large-scale plasmid extraction. amp-ccdB was removed by AscI at 37°C for 2h, and the linearized fragment with amp-ccdB removed was obtained by phenol-chloroform extraction and ethanol precipitation. The above precipitated fragments and the targeting peptide Co1 / DCpep / Co1+DCpep tandem PEDV S gene COE+S1D fragments with ORF3a homology arms amplified in step 1 were respectively assembled by Gibson in vitro and transformed into E. coli GB2005 to obtain the recombinant plasmids pBeloBAC11-cm-CI-SADS-CoV-WT-HDVrz-SV40polyA-△ORF3a-PEDV S(COE+S1D)-Co1, pBeloBAC11-cm-CI-SADS-CoV-WT-HDVrz-SV40polyA-△ORF3a-PEDV S(COE+S1D)-Co1, and pBeloBAC11-cm-CI-SADS-CoV-WT-HDVrz-SV40polyA-△ORF3a-PEDV S(COE+S1D)-Co1, and pBeloBAC11-cm-CI-SADS-CoV-WT-HDVrz-SV40polyA-△ORF3a-PEDV S(COE+S1D)-DCpep, pBeloBAC11-cm-CI-SADS-CoV-WT-HDVrz-SV40polyA-△ORF3a-PEDV S(COE+S1D)-Co1-DCpep. Pick a single colony, extract the plasmid, and perform enzyme digestion verification and PCR verification.

[0092] The primers used in the above PCR verification and sequencing are shown in SEQ ID NOs. 10-11.

[0093] PCR program: 94°C for 5 min; 98°C for 10 s, 55°C for 5 s, 72°C for 20 s, set for 32 cycles; 72°C for 10 min extension, stored at 4°C. PCR system: PrimeSTAR Max DNA Polymearse 15 μL, upstream and downstream primers (10 pmol / μL) 1 μL each (Table 5), template 1 μL, add ddH2O to make up to 30 μL.

[0094] The schematic diagram of the construction of the recombinant plasmids with the targeting peptide Co1 / DCpep / Co1+DCpep tandem with the PEDV S gene COE+S1D inserted into the ORF3a position is shown in the figure. Figure 1 The amplification results of the linear fragment preparation are shown in Figure 2 As shown in the figure. The restriction analysis and PCR amplification of the recombinant plasmids with the targeting peptide Co1 / DCpep / Co1+DCpep tandem with the PEDV S gene COE+S1D were respectively inserted into the ORF3a position. Figure 3and Figure 4 shown.

[0095] Example 2 Virus rescue of recombinant plasmid

[0096] 1. Extract plasmid using kit: Inoculate the constructed recombinant plasmid into 200 mL of culture medium, culture overnight, and extract the plasmid using Aidlab BAC / PAC large plasmid extraction kit.

[0097] 2. Co-transfection of recombinant plasmid and auxiliary plasmid into Vero cells: After detecting the concentration of recombinant plasmid and auxiliary plasmid, use Lipofectamin 3000 kit ( 3000 Reagent purchased from invitogen) was used for transfection experiments.

[0098] 3. Rescue virus and subculture: Subculture the virus solution obtained after transfection on Vero cells. When the Vero cells are full, discard the supernatant, wash twice with PBS, add the virus solution and DMEM culture solution containing 8ug / mL trypsin, shake evenly, incubate in a 37℃, 5% CO2 incubator for 1h, discard the supernatant, add an appropriate amount of DMEM culture solution containing 8ug / mL trypsin, collect the virus 48h after infection, place it in a -80℃ refrigerator and freeze and thaw once, collect the virus solution, subculture the virus according to this method, observe the virus pathological changes, and record the generations as F1, F2, F3, etc. The recombinant viruses were named rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1, rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-DCpep, and rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1-DCpep, respectively.

[0099] The COE+S1D fragment connected with the targeting peptide gene is inserted at 23878bp to 24531bp of the recombinant porcine acute diarrhea syndrome coronavirus.

[0100] The nucleotide sequence of the COE+S1D fragment of the porcine epidemic diarrhea virus S gene concatenated with the M cell targeting peptide Co1 is shown in SEQ ID NO.15;

[0101] The nucleotide sequence of the COE+S1D fragment of the S gene of porcine epidemic diarrhea virus connected in series with the DC cell targeting peptide DCpep is shown in SEQ ID NO.16;

[0102] The nucleotide sequence of the porcine epidemic diarrhea virus S gene COE+S1D concatenated with the M cell targeting peptide Co1 and the DC cell targeting peptide DCpep is shown in SEQ ID NO.17;

[0103] 4. PCR detection and sequencing verification of rescued viruses: After continuous passage, stable lesions appeared, cell membrane fusion was syncytial, and vacuoles appeared ( Figure 5 At the same time, the supernatant was collected after freezing and thawing the virus-infected samples, and the RNA of the recombinant virus was extracted using the AxyPrep body fluid virus DNA / RNA small kit (product of Axygen). After reverse transcription into cDNA, primers were designed for PCR detection to detect the ORF3a gene of the recombinant virus. The results are shown in Figure 6 The results of each lane were consistent with expectations and were different from the unmodified rescued virus rSADS-CoV-WT. The subsequent sequencing results confirmed that the recombinant virus sequence was consistent with expectations, indicating that the rescued recombinant viruses all carried the corresponding exogenous genes. The PCR detection and sequencing primer sequences are shown in SEQ ID NO.10-11, and the PCR products were detected by 1% agarose gel electrophoresis.

[0104] 5. Evaluation of the stability of the rescued virus after inserting the exogenous gene: The rescued virus was continuously subcultured for 15 generations on Vero cells, and its pathological changes were observed. PCR was used to identify whether the target gene existed stably. The PCR amplification results are shown in Figure 7 It can be seen that the F15 generation of the three recombinant viruses all have the same bands as the F2 generation, and the size of the target fragment is in line with expectations, indicating that the inserted exogenous gene targeting peptide Co1 / DCpep / Co1+DCpep tandem PEDV S (COE+S1D) can all be stably present. The PCR detection primer sequences are shown in SEQ ID NO.10-11, and the PCR products are detected by 1% agarose gel electrophoresis.

[0105] Example 3 Determination of rescued virus titer and plotting of its growth curve

[0106] Vero cells were plated in advance, and after the 96-well plate was filled with monolayer cells, the recombinant viruses were respectively -1 ~10 -10 Ten-fold serial dilutions were inoculated into 96-well cell culture plates, with 8 wells inoculated for each dilution. The last two columns were not inoculated as blank controls. The plates were cultured in a 37°C, 5% CO2 cell culture incubator. The cytopathic effects were observed for 5 consecutive days. The TCID of the virus was calculated according to the Reed-Muench method. 50 .

[0107] A T75 culture flask filled with Vero cells was inoculated at a dose of 0.01 MOI. After incubation for 1 h, the culture medium was replaced with DMEM culture medium containing 8 μg / mL trypsin. At different time points after infection (0, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60, 72 h), 200 μL of cell supernatant was collected, and the viral RNA was extracted and the viral copy number in each time period was determined by fluorescence quantitative method and plotted into a curve.

[0108] The detection gene is N, the primer sequences are SADS-qF (SEQ ID NO.9): 5'-CTGACTGTTGTTGAGGTTAC-3', SADS-qR (SEQ ID NO.10): 5'-TCTGCCAAAGCTTGTTTAAC-3', and the probe sequence is SADS-probe (SEQID NO.11): 5'6-FAM-TCACAGTCTCGTTCTCGCAATCA-3'TAMRA-N. The fluorescence quantitative system is: 2×OneStep U + Mix 10μL, One Step U + Enzyme Mix 1μL, upstream and downstream primers and probe (10μM) 0.4μL each, template 2μL, RNase-Free ddH2O to make up to 20μL. Figure 8 As shown, the recombinant viruses rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1, rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-DCpep, and rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1-DCpep all have growth kinetics curves similar to those of the original rescued virus rSADS-CoV-WT, reaching a peak at 48h on Vero cells and then tending to be stable. The overall growth trend is consistent and there is no significant difference, indicating that the recombinant viruses rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1, rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-DCpep, and rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1-DCpep rescued by the present invention have replication capabilities similar to those of the original virus.

[0109] Example 4 Detection of rescued virus exogenous protein expression

[0110] 1. WB detection of rescued virus exogenous protein

[0111] The rescued virus was inoculated at 0.01 MOI into a six-well plate covered with a monolayer of Vero cells. After adsorption for 1 hour, the culture medium was replaced with DMEM culture medium containing 8 μg / mL trypsin. When the degree of lesions was close to 100%, the six-well plate was collected, the supernatant was discarded, and 1% PMSF was added to RIPA Lysis Buffer (CWBIO) after washing twice with PBS. After lysis on ice for 30 minutes, centrifuged at 4°C for 20 minutes, 5x SDS Buffer was added, and the total cell protein was harvested by boiling for 10 minutes.

[0112] According to the instructions of the protein gel kit, the separation gel and the concentrated gel were prepared for SDS-PAGE electrophoresis. Take an equal amount of each sample protein solution and add it to the protein gel. End the electrophoresis after 100V and 1h30min. Add the pre-cooled transfer solution to the transfer tank, cut the PVDF membrane according to the size of the target protein, activate the PVDF membrane with anhydrous ethanol, set a constant current of 220mA for 1h for transfer, and place it in the rapid blocking solution for 1h at room temperature after the transfer. Dilute the primary antibody at a ratio of 1:1000 and incubate at room temperature for 2h; then wash it with TBST 5 times and shake it on a shaker for 5min each time. Dilute the secondary antibody at a ratio of 1:10000, incubate it at room temperature for 1h, and wash it with TBST 5 times for 5min each time. Put the membrane in the exposure instrument, drip the chemiluminescent liquid on the membrane, and adjust the instrument parameters for exposure.

[0113] The results are as follows Fig. 9 As shown, from Fig. 9 It can be seen that compared with the blank group Mock, the three recombinant viruses can express the corresponding exogenous proteins at the protein level, indicating that the recombinant viruses carrying the exogenous gene targeting peptide Co1 / DCpep / Co1+DCpep tandem with PEDV S gene COE+S1D all have the ability to express exogenous proteins and are immunogenic.

[0114] 2. IFA detection of rescued virus exogenous protein

[0115] The rescued virus was inoculated into a twelve-well plate covered with a monolayer of Vero cells at 0.01 MOI. After adsorption for 1 hour, it was replaced with DMEM culture medium containing 8μg / mL trypsin. When the lesion reached about 50%, the twelve-well plate was collected, the supernatant was discarded, and 4% paraformaldehyde was added after washing with PBS twice, and fixed at 4℃ for 30 minutes. Wash PBS three times, add 0.2% Triton-X100, and permeabilize the cells at room temperature for 15 minutes. Then use 5% skim milk to block at room temperature for 1 hour, wash with TBST three times after blocking, and shake on a shaker for 5 minutes each time. The primary antibody was diluted at a ratio of 1:500, incubated at room temperature for 2 hours, and then washed with TBST three times, shaken on a shaker for 5 minutes each time. The secondary antibody was diluted at a ratio of 1:1000, incubated at room temperature in the dark for 1 hour, and washed with TBST three times, each time for 5 minutes. Anti-fluorescence quenching sealing liquid (containing DAPI) was added to the sample, and the sample fluorescence was observed using a fluorescence inverted microscope after evenly covering it.

[0116] The results are as follows Fig.10 As shown, it can be seen that: compared with the blank control group Mock, obvious target fluorescence can be observed in the field of view of the three recombinant virus-infected samples, and the fluorescence position corresponds to the lesion site, further proving that the recombinant viruses carrying the exogenous gene targeting peptide Co1 / DCpep / Co1+DCpep tandem with PEDV S gene COE+S1D all have the ability to express exogenous proteins and are immunogenic.

[0117] Example 5 Detection of dendritic cell subsets and T lymphocyte subsets after rescue virus immunization of sows

[0118] The rescued viruses rSADS-CoV-WT-△NS3a-PEDV(COE+S1D), rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1, rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-DCpep, and rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1-DCpep were added at 2.0×10 6.4 TCID 50 The sows were immunized with a dose of 100 mg / kg / day and boosted with the same dose 9 days before farrowing. Anticoagulated peripheral blood was collected from the sows when they farrowed for flow cytometric analysis of dendritic cell subsets CD11c, CD80 and T lymphocyte subsets CD3+CD4+, CD3+CD8+.

[0119] The results are as follows Fig.11As shown, it can be seen that the proportion of CD80 and CD11c in the recombinant virus immunization group with inserted targeting peptides is higher than that in the commercial inactivated vaccine immunization group and the recombinant virus immunization group without targeting peptides, among which the CD11c percentage of the rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1 immunization group is significantly different from that of the blank control group (P≤0.05); the proportion of CD3+CD4+ and CD3+CD8+ in the recombinant virus immunization group with inserted single targeting peptide Co1 and dual targeting peptide Co1+DCpep is higher than that in the commercial inactivated vaccine immunization group and the recombinant virus immunization group without targeting peptides. In summary, the three recombinant viruses with inserted targeting peptides can better stimulate the mucosal immune response of sows, and the recombinant viruses with inserted single targeting peptide Co1 and dual targeting peptide Co1+DCpep can also better stimulate the cellular immune response of sows.

[0120] Example 6 ELISA detection of serum IgG levels in piglets before PEDV challenge

[0121] In order to evaluate the maternal antibodies obtained by piglets from immunized sows, the IgG level of PEDV S protein in the serum of piglets before the challenge (5 days old) was evaluated using an ELISA kit. Fig.12 As shown, compared with the negative control group, the IgG level in the serum of piglets in each immunization group was higher before virus challenge, and the IgG level of piglets in the three recombinant virus immunization groups was slightly higher than that in the commercial inactivated vaccine immunization group, indicating that the three recombinant viruses all have a good effect of stimulating PEDV IgG level.

[0122] Example 7 Evaluation of clinical protection effect after PEDV challenge in piglets

[0123] 1. Clinical cumulative diarrhea score of piglets after virus challenge

[0124] In order to verify the clinical protective effect of piglets passively immunized with the recombinant virus, the clinical symptoms of the piglets were observed every day after the virus challenge and the cumulative diarrhea scores were calculated for 8 days. The scoring rules for the degree of diarrhea in piglets are: 0 points, normal without diarrhea; 1 point, mushy feces; 2 points, thin feces; 3 points, watery diarrhea / death. The results showed that the negative control group had no disease throughout the whole process and no cumulative diarrhea score; the positive control group had obvious severe diarrhea and the highest cumulative diarrhea score; the diarrhea scores of each recombinant strain immunization group were lower than those of the commercial inactivated vaccine immunization group, among which the dual-target peptide rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1-DCpep immunization group had the lowest cumulative diarrhea score, and had better clinical protection effect than the other two recombinant viruses ( Fig.13 ).

[0125] 2. Survival curve of piglets after virus challenge

[0126] In order to verify the clinical protective effect of passive immunization of piglets with recombinant virus, the survival of piglets was recorded every day after the piglets were challenged with the virus. Fig.14 As shown, the survival rate of piglets in the positive control group after virus attack was 75%; among each immunization group, except for one piglet that died in the rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-DCpep immunization group with a single DC cell targeting peptide inserted, the survival rate of piglets in the other immunization groups after virus attack was 100%, indicating that immunization of pregnant sows with recombinant strains inserted with targeting peptides Co1 and Co1+DCpep can provide better immune protection for their lactating piglets.

[0127] 3. Cumulative daily weight gain of piglets after virus challenge

[0128] In order to verify the effect of PEDV on the weight of piglets after challenge, the piglets were weighed every day for 14 days after the challenge. The results showed that the weight of piglets in the positive control group continued to decline within 9 days after the challenge; the weight of piglets in each immunization group only increased slowly within 7 days after the challenge, but there was no significant decrease. Among the recombinant strain immunization groups, starting from the 9th day after the challenge, the rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1-DCpep immunization group with dual targeting peptides had the fastest weight gain and the best overall condition, indicating that the dual targeting peptide recombinant virus has better clinical protection effect after immunization than the other two recombinant viruses ( Fig.15 ).

[0129] 4. Daily detoxification testing of piglets after virus attack

[0130] In order to verify the difference in virus excretion in each group of piglets after PEDV challenge, anal swabs were collected every day after the piglets were challenged for absolute fluorescence quantitative detection of viral DNA copy number. The results showed that each group reached the peak of virus excretion 3 to 5 days after the virus challenge, and the detoxification trend of each immune group after the peak of virus excretion was basically the same. Compared with the positive control group, the detoxification time was shorter and the detoxification amount was smaller. Among them, the rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1-DCpep immune group with dual targeting peptides had a lower detoxification amount at 0 to 5 days after the virus challenge than other immune groups, indicating that the impact of PEDV on the piglets in the immune group of the recombinant strain after the virus challenge was shorter and smaller, and the piglets recovered faster ( Fig.16 ).

[0131] Example 8 Observation and detection of lesions after autopsy of piglets challenged with PEDV

[0132] 1. Autopsy of intestinal lesions in piglets after virus attack

[0133] On the 8th day after the piglets were challenged with the virus, 3 piglets were randomly selected from each group for autopsy. The results showed that the piglets in the positive control group F had obvious thinning and transparency of the intestinal wall, and the lesions were obvious; the piglets in the negative control group G, rSADS-CoV-WT-△NS3a-PEDV (COE+S1D) immunization group A, rSADS-CoV-WT-△NS3a-PEDV (COE+S1D)-Co1 immunization group B, rSADS-CoV-WT-△NS3a-PEDV (COE+S1D)-DCpep immunization group C, rSADS-CoV-WT-△NS3a-PEDV (COE+S1D)-Co1-DCpep immunization group D, and PEDV commercial inactivated vaccine immunization group E had no obvious intestinal lesions. This shows that immunizing pregnant sows with recombinant strains can provide better immune protection for their lactating piglets ( Fig.17 ).

[0134] 2. Quantitative detection of pathogens in small intestinal tissue of piglets after virus attack

[0135] On the 8th day after the piglets were challenged with the virus, 3 piglets were randomly selected from each group for autopsy, and samples of the duodenum, jejunum, and ileum were collected for absolute fluorescence quantitative detection of viral DNA copy number. The results showed that the duodenum, jejunum, and ileum all carried PEDV pathogens, among which the positive control group piglets carried the highest number of viral DNA copies in each part of the intestine, and the rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1-DCpep immunization group with dual targeting peptides inserted in each immunization group carried a lower number of viral DNA copies overall. The number of viral DNA copies carried in the jejunum of piglets immunized with rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1 inserted with a single targeting peptide and rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1-DCpep inserted with dual targeting peptides was significantly reduced compared with the positive control group (P≤0.05). The number of viral DNA copies carried in the jejunum of piglets immunized with rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-DCpep inserted with a single targeting peptide was extremely significantly reduced compared with the positive control group (P≤0.01). Among the four recombinant virus immunization groups, the three recombinant virus immunization groups with inserted targeting peptides had lower viral DNA copy numbers in the small intestine tissue of piglets than the rSADS-CoV-WT-△NS3a-PEDV (COE+S1D) immunization group without added targeting peptides, indicating that the recombinant virus with inserted targeting peptides can better protect the small intestine tissue of piglets from PEDV infection by passive immunization ( Fig.18 ).

[0136] 3. H&E staining of small intestinal tissue pathological sections of piglets after virus challenge

[0137] The duodenum, jejunum, and ileum of the piglets after the virus attack were stained with H&E tissue pathological sections. Fig.19 As shown, after PEDV challenge, the small intestinal tissue of the piglets in the positive control group was significantly damaged, and the integrity of the small intestinal villi was poor, while in the other groups, the jejunal damage of the piglets in the rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-DCpep immunization group, which only inserted a single targeting peptide, was more serious, and the small intestinal villi of the piglets in other groups were intact and there was no obvious damage to the small intestinal tissue. The above results show that immunizing pregnant sows with recombinant strains inserted with single targeting peptide Co1 and dual targeting peptide Co1+DCpep can provide better immune protection for their lactating piglets and reduce tissue damage caused by viral infection after PEDV challenge.

[0138] 4. Immunohistochemistry of small intestinal tissue pathological sections of piglets after virus challenge

[0139] Immunohistochemistry was performed on the duodenum, jejunum, and ileum of the piglets after the virus attack. Fig. 20 As shown in the figure, the small intestinal tissue antigen coloration of the positive control group after PEDV challenge was obvious, while the small intestinal tissue antigen coloration of the other immunized groups was less. The above results further indicate that pregnant sows immunized with recombinant strains can provide better immune protection for their suckling piglets and reduce the infection of the virus to the small intestinal tissue after PEDV challenge.

[0140] Summarize:

[0141] 1. Based on CN114657213B, the present invention successfully inserted three COE+S1D genes with targeting peptide genes, and verified that the recombinant virus of the present invention is effective and successful from multiple perspectives such as protein expression, immune-related cytokines, and animal protection effects;

[0142] 2. The expression of immune-related factors was evaluated from multiple perspectives, including CD80, CD11c, CD3+CD4+, and CD3+CD8+. It can be seen that the expression of related immune factors of rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1 was the most significant, significantly better than rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1-DCpep, and especially better than rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-DCpep.

[0143] From this perspective, an important factor in achieving increased expression of immune-related factors and improving immune performance is the targeting peptide Co1. Compared with recombinant viruses that are not linked to any targeting peptides, the targeting peptide DCpep inhibits the expression of immune factors (such as CD3+CD4+ and CD3+CD8+).

[0144] It can be seen that the expression of dual targeting in immune factors is contrary to the applicant's previous prediction, and the results of rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1 in the expression of relevant immune factors are unpredictable.

[0145] 3. From the results of animal virus challenge, rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1-DCpep has the best effect. The analysis of viral load in different organ locations shows that rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-DCpep has more advantages in the duodenum and jejunum, and rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1 has a more obvious advantage in the ileum;

[0146] In general, the effect of rSADS-CoV-WT-△NS3a-PEDV(COE+S1D)-Co1-DCpep is the best.

[0147] The applicant declares that the present invention illustrates the process method of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned process steps, and it does not mean that the present invention must rely on the above-mentioned process steps to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of the raw materials selected by the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

Claims

1. A recombinant porcine acute diarrhea syndrome coronavirus, characterized in that: The ORF3a gene of SADS-CoV was obtained by replacing the COE+S1D fragment of the S gene of porcine epidemic diarrhea virus connected with the targeting peptide gene; The COE+S1D fragment refers to a tandem epitope formed by connecting the COE antigenic epitope and the S1D antigenic epitope of the S gene of porcine epidemic diarrhea virus in series; The porcine epidemic diarrhea virus S gene COE+S1D fragment connected with the targeting peptide gene is a porcine epidemic diarrhea virus S gene COE+S1D fragment connected in series with the M cell targeting peptide Co1 or connected in series with the M cell targeting peptide Co1 and the DC cell targeting peptide DCpep; The preparation method of the recombinant porcine acute diarrhea syndrome coronavirus is as follows: Step 1: Load the homology arms to both ends of amp-ccdB by PCR to obtain an amp-ccdB screening marker fragment with ORF3a homology arms at both ends; Step 2: by PCR, the M cell targeting peptide Co1 and homology arms are added to the right side and both ends of the COE+S1D region of the PEDV S gene to obtain a PEDV S gene COE+S1D fragment with the targeting peptide Co1 and the ORF3a homology arms, or, by PCR, the M cell targeting peptide Co1, the DC cell targeting peptide DCpep and homology arms are added to the right side and both ends of the COE+S1D region of the PEDV S gene to obtain a PEDV S gene COE+S1D fragment with the targeting peptide Co1+DCpep and the ORF3a homology arms; Step 3: The amp-ccdB screening marker fragment in step 1 is recombined with the pBeloBAC11-cm-CI-SADS-CoV-WT-HDVrz-SV40polyA infectious clone through DNA homologous recombination engineering; Step 4: Use the preset restriction site to cut off the amp-ccdB screening marker fragment, and use Gibson assembly with the PEDV S gene COE+S1D fragment with the targeting peptide and ORF3a homology arm obtained in step 2 to obtain the targeting peptide Co1+DCpep tandem PEDV S gene COE+S1D recombinant plasmid replacing the ORF3a gene or the targeting peptide Co1 tandem PEDV S gene COE+S1D recombinant plasmid; The targeting peptide Co1+DCpep is connected in series with the PEDV S gene COE+S1D recombinant plasmid or the targeting peptide Co1 is connected in series with the PEDV S gene COE+S1D recombinant plasmid to obtain the recombinant porcine acute diarrhea syndrome coronavirus through virus rescue.

2. Use of the recombinant porcine acute diarrhea syndrome coronavirus as claimed in claim 1 in the preparation of a vaccine for preventing and treating porcine epidemic diarrhea virus and / or porcine acute diarrhea syndrome coronavirus.

3. A vaccine, characterized in that Contains the recombinant porcine acute diarrhea syndrome coronavirus as described in claim 1.